Psychological interventions are the treatment of choice for most eating disorders; however, significant proportions of patients do not recover with these. Advances in understanding of the neurobiology of eating disorders have led to the development of targeted treatments, such as deep brain stimulation (DBS), noninvasive brain stimulation (NIBS), and neurofeedback. We review the emerging clinical evidence for the use of these interventions in eating disorders and obesity, together with their theoretical rationale. Finally, we reflect on future developments.
INTRODUCTION
Neuromodulation has been defined as use of 'advanced medical device technologies to enhance or suppress activity of the nervous system for the treatment of disease. These technologies include implantable as well as nonimplantable devices that deliver electrical, chemical, or other agents to reversibly modify brain and nerve cell activity' [1] . These therapies are reversible and highly targeted to specific areas of the brain or spinal cord.
Improved understanding of the neurocircuitry involved in eating disorders and obesity [2, 3, 4 && ] has given rise to the use of neuromodulation and neurofeedback as illness probes and as emerging treatments [5] . In particular, researchers have implicated alterations in circuits involved in reward processing [6] [7] [8] [9] , affect, stress and negative valence [10, 11] , appetite regulation [12, 13] , and self-regulatory control [6, 9] . To explain the extremes of behavior across the spectrum of eating disorders (from severe food restriction/undereating to overeating/ binge eating), it has been proposed that these may result from a differentially altered balance between neural mechanisms of reward and inhibitory processing [9] . Neurobiological overlaps between eating disorders, obesity, and addictions are being proposed [14] [15] [16] .
The review will focus on the most promising neuromodulation techniques, deep brain stimulation (DBS), repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and neurofeedback [3, 17, 18] . We will describe these techniques and stimulation targets, describe potential underlying mechanisms,
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Deep brain stimulation
DBS is a reversible neurosurgical intervention, whereby electrodes are implanted into a defined brain region and a battery-operated pulse generator (usually implanted in the chest) sends electrical pulses to the region to alter neural activity. Once implanted, the DBS device can be activated and programmed wirelessly, permitting real-time titration of stimulation parameters. Case studies of DBS to improve anorexia nervosa or comorbid symptoms (obsessive compulsive disorder, depression), targeting the nucleus accumbens, subgenual cingulate cortex, ventral capsule/ventral striatum, or subcallosal cingulate, have shown promise in highly selected severe and enduring cases (for review see [3, 18] ). As yet, no randomized controlled trials (RCTs) have been carried out. Likewise in cases of severe obesity, hypothalamic or nucleus accumbens DBS has shown promise (for review see [19 & ]).
Noninvasive brain stimulation
In transcranial magnetic stimulation (TMS), an electrical current is passed through a TMS coil, thus generating a magnetic field. When the coil is held against the head, the field induces a secondary electrical current (i.e., activation of neurons) in the targeted brain region. rTMS involves the delivery of multiple pulses over a short time period with effects that outlast the stimulation period (30-60 min) . Low frequency rTMS (<5 Hz) is thought to suppress neural activity, but high frequency rTMS (>5 Hz) is thought to enhance activity [20] .
tDCS is a noninvasive form of brain stimulation. It involves the application of a low-intensity constant current (1-2 mA) directly to the brain via scalp electrodes, which is thought to alter the electrical potential of neuronal membranes. Anodal (þ terminal) stimulation generally has cortical excitatory effects, whereas cathodal (-terminal) stimulation inhibits activity. Effects on cortical excitability can last beyond the stimulation period -up to 90 min. Long-term effects seem to operate through modifications of postsynaptic nerve connections, similar to long-term potentiation and long-term depression [20] .
Candidate targets for noninvasive brain stimulation (NIBS) in eating disorders, based on a 'Research Domain Criteria (RDoC) formulation' of eating disorder-related psychopathology have been described [4 && ]. These include targets in the cognitive control, positive and negative valences, and social processes systems. For pragmatic accessibility reasons, studies have targeted the dorsolateral prefrontal cortex (DLPFC) or the dorsomedial prefrontal cortex (DMPFC) [4 && ,21] . Several case studies, case series, and proof-of-concept RCTs of NIBS have shown promise in eating disorders, obesity, and food craving [22] [23] [24] [25] [26] .
Neurofeedback
Neurofeedback trains individuals to voluntarily regulate their brain activity in a target area in response to real-time feedback [27] . The level of neural activity, as assessed via electroencephalography (EEG) or functional neuroimaging (fMRI), is fed back to the individual using a brain-computer interface and this provides continuously updated information about their success in regulating their neural activity [2, 17] .
EVIDENCE SUPPORTING DIFFERENT TYPES OF NEUROMODULATION AND NEUROFEEDBACK IN EATING DISORDERS AND OBESITY
To provide an overview of recent clinical studies of invasive and noninvasive neuromodulation and neurofeedback in eating disorders and obesity, we
KEY POINTS
During the last 20 months, several case studies/series and RCTs of NIBS, DBS, and neurofeedback in different eating disorders, obesity, or food craving have appeared, with largely promising results.
Ongoing trials in eating disorders and obesity will increase the evidence base for neuromodulation and neurofeedback procedures and help establish the validity of treatment protocols.
Combining neuroimaging and neuromodulation techniques may help to identify distinct neural endophenotypes associated with differential intervention responses and may shed light on illness mechanisms.
Much still needs to be learnt about patient selection, intervention parameters, treatment targets, and how to optimize protocols.
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Deep brain stimulation
Our search identified one single case study of DBS in anorexia nervosa [28] and one open label trial of DBS, targeting the subcallosal cingulate cortex in 16 patients with chronic treatment-refractory anorexia nervosa [29 & ] (see Table 1 ). This was an extension of an earlier series of six patients [65] and is the largest series of DBS for anorexia nervosa. DBS treatment was associated with significant and sustained improvements in anxiety, depression, and emotion regulation, and significant increases in BMI at 12 months postsurgery [29 & ]. PET imaging showed significant changes in glucose metabolism in brain structures implicated in anorexia nervosa at 6 and 12 months follow-ups, compared with baseline, suggesting that DBS can directly affect anorexiarelated brain circuitry. Two patients asked to have their device removed for poorly explained reasons. A total of 10 out of 16 patients experienced at least one adverse event; however, only one was thought to be DBS related (surgical site infection), most others were related to the underlying illness. A single case study of nucleus accumbens DBS in obesity was also identified [30] .
Noninvasive brain stimulation
We identified eight NIBS studies (n ¼ 232 participants), all targeting the DLPFC (see Table 2 ).
Anorexia nervosa
Two studies assessed use of rTMS in anorexia nervosa. In a sham-controlled RCT, a single session of real rTMS led to greater short-term reduction in eating disorder symptoms and improved rewardrelated decision-making (assessed through a temporal discounting paradigm) [31 & ]. In a subsequent case series, five adults with severe and enduring anorexia nervosa received 20 sessions of real rTMS [32] . This was associated with reductions in eating disorder and affective symptoms. Improvements persisted up to 6 months posttreatment but had waned by 12 months.
Bulimia nervosa
Recent NIBS studies have shown mixed results in bulimia nervosa. A case series of single-session highfrequency rTMS found reductions in food craving and hunger, but no change in eating disorder symptoms [33] .
Likewise, a sham-controlled RCT of 10 sessions of high-frequency rTMS in bulimia nervosa participants found no difference between groups in eating disorder symptoms posttreatment [34 & ]. However, the study was limited, in that the stimulation target was not localized by neuronavigation and the number of rTMS sessions was relatively low.
In contrast, a crossover RCT using tDCS in bulimia nervosa found that one session of anode right/ cathode left active tDCS (but not anode left/cathode right active or sham tDCS) leads to improvements in cognitions and mood at posttreatment [35 & ]. Both active tDCS conditions suppressed the self-reported urge to binge eat and increased self-regulatory control (assessed through temporal discounting paradigm). Group differences in frequency of eating disorder symptoms were not observed 24-h posttDCS.
Food craving, binge eating disorder, and obesity A study of healthy individuals with high food cravings, found active tDCS applied over 5 consecutive days significantly reduced food cravings in comparison to sham tDCS, both posttreatment and 1 month later [36] .
In a crossover study, participants with binge eating disorder experienced reduced cravings for certain foods and consumed fewer calories following a single session of active tDCS, compared to sham
Participants with obesity consumed fewer kilocalories/day from fat and soda and had a greater percentage weight loss, during active anodal tDCS treatment to the left DLPFC, compared to during cathodal tDCS [38] . There was no difference between sham and active groups in relation to weight change or food intake. Treatments in eating disorders and obesity Dalton et al.
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www.co-psychiatry.com ]. In this proof-of-principle study, participants successfully managed to increase functional connectivity between the DLPFC and ventromedial prefrontal cortex, areas of the brain associated with executive control and reward processing. Despite this, there was only a trend effect of neurofeedback training on food choice toward less high-calorie foods.
Ongoing studies of neuromodulation and neurofeedback Details of 21 ongoing studies are presented in Table 4 . The majority are trials of NIBS, with roughly equal numbers of rTMS and tDCS protocols. For both modalities, the majority of studies involve multiple sessions, targeting the prefrontal cortex. In addition, there are five DBS studies in progress, three in anorexia nervosa, and two in obesity. These trials will increase the evidence base for these procedures and help establish the validity of treatment protocols.
AN EMERGING SCIENTIFIC RATIONALE FOR THE USE OF NEUROMODULATION/ NEUROFEEDBACK
It is beyond the scope of this article to discuss extensively the evidence relating to different putative mechanisms of action underpinning different neuromodulation treatments. The interested reader may wish to consult the following reviews (e.g. [20, 66, 67] ). Here, we briefly focus on two promising areas of investigation, the combination of neuroimaging and neuromodulation data, and the role of mechanisms related to memory reconsolidation.
Neural correlates and predictors of change
Studies combining neuroimaging and neuromodulation data are in their infancy in eating disorders. Such studies might be able to identify distinct neural endophenotypes, associated with differential intervention responses at the neural and the clinical level; they might also help tailor rTMS parameters to individual patients and they may shed light on illness mechanisms and strengthen the scientific rationale for the use of neuromodulation [68] . The first functional neuroimaging study in eating disorders patients undergoing NIBS involved 28 patients with longstanding binge-purge behaviors and failed previous treatments [68] . All received 20-30 sessions of 10 Hz DMPFC-rTMS. On the basis of a criterion of at least 50% reduction in weekly binge/ purge frequency, participants were stratified into 16 treatment responders and 12 nonresponders. There were widespread differences between the two groups in resting-state neural connectivity at baseline. Relative to nonresponders, rTMS responders showed baseline hypoconnectivity from the stimulation target to other cortical and subcortical regions. In responders, frontostriatal connectivity was enhanced following DMPFC-rTMS, in association with reductions in binge-purge frequency. Conversely, in patients with higher baseline connectivity, DMPFCrTMS had the opposite effect, reducing frontostriatal connectivity, in association with worsening of or failure to improve symptoms. The need to conceptualize change in terms of neural networks in relation to neuromodulation in psychiatric disorders has been reviewed [69 && ].
The role of learning and memory reconsolidation
As described, many studies emphasize the importance of motivational salience, reward and learned behaviors, and are consistent with neuromodulation that targets frontostriatal circuits. However, it is important to recognize the emerging role of learning in the development/maintenance of psychiatric illnesses, such as eating disorders, and the role of new learning in treatment [70, 71] . For this reason, it is appropriate to consider the neural underpinnings of memory as a potential neuromodulation target.
Of particular clinical interest is reconsolidation, the process by which memories can be made labile via reactivation (e.g. [72, 73] ). Reconsolidation is increasingly being used as a treatment target based on the assumption that psychological treatments are most effective when links between illnessrelevant stimuli and maladaptive emotional, cognitive, or behavioral responses are broken (e.g. [70] ). This is the objective of exposure treatments [74, 75] ; however, an alternative approach is to update emotional memories by changing their salience during reconsolidation [76] , using psychological or (e.g. [77] [78] [79] ) pharmacological approaches (e.g. [80] [81] [82] [83] ). Importantly, neuromodulation reportedly alters memory reconsolidation and some studies have begun to assess the effects of tDCS on reconsolidation [84] . Mechanisms center around the proposal that new memories arise when the balance between excitatory (glutamatergic) and inhibitory Gamma-aminobutyric acid (GABA-ergic) (E-I) firing patterns are disrupted [61, 62] , as can be promoted by neuromodulation. For example, tDCS has been shown to decrease GABA concentrations and hence may modulate the relationship between glutamate and GABAergic systems [61] . On the basis of such studies, our opinion is that molecular/physiological studies related to neuromodulation will need to identify which neurotransmitter systems are the main targets, for example, 5-hydroxytryptamine (in relation to affect regulation), Dopamine (in relation to reward and habits) and/or glutamate/GABA (E-I) (in relation to memory and synaptic plasticity). The importance of E-I systems in psychopathology and across psychiatric phenotypes has recently been discussed (e.g. [85] ). But, if explanatory models of neuromodulation increasingly center around E-I systems, neuromodulation might be most effective as an adjunct to treatments involving memory reconsolidation. Lastly, the E-I balance and its relation to synaptic plasticity is an evolving issue and the complexity involved is likely to increase.
ACCEPTABILITY, SAFETY, AND ETHICAL CONSIDERATIONS
In general, safety and acceptability of NIBS do not appear to be a problem (e.g. [86] [87] [88] ). For example, a systematic review of tDCS studies found similarly low dropout rates for real and sham tDCS [87] . However, these authors noted that the quality of adverse events reporting was low in most studies. Very limited research on this issue has been conducted in relation to eating disorders [89] . Ethical considerations have mainly focused on DBS rather than on NIBS, given the invasiveness of DBS and its use in highly vulnerable, physically frail anorexia nervosa patients, whose capacity for making health-related decisions may be impaired. Additionally, families desperate to alleviate their loved ones distress may push them toward agreeing to DBS. Other concerns have included the issue that DBS or NIBS might be perceived as 'mind control', increasing patients' helplessness and reducing their sense of authenticity [90, 91] . The limited literature exploring eating disorder patients' views shows that they are able to understand and reflect on issues related to gains and threats to their authenticity [92, 93] . In a case series (n ¼ 5) of therapeutic rTMS in anorexia nervosa, patients were asked about their experience [32] . They talked about greater cognitive clarity, flexibility, and improved mood. There was no sense of altered authenticity or agency. Recently, a neuroethics framework for the use of DBS in anorexia nervosa has been published [94] .
DISCUSSION
During the last 20 months, seven case studies/series and seven RCTs of NIBS or neurofeedback in different eating disorders, obesity, or food craving have appeared, with largely promising results. However, one NIBS trial, using a multisession protocol in bulimia nervosa, was negative. A case series of subcallosal DBS in anorexia nervosa has also shown promise. A search of trial registries identified a further 21 eating disorder-focused neuromodulation/ feedback studies in progress, suggesting that this is an area of growing interest. In parallel, safety, acceptability, and ethical considerations are being systematically studied. Progress is also being made in relation to developing a rationale for use of neuromodulation treatments, substantially based on neural models of eating disorders/obesity, including the role of memory and its reconsolidation in their development and treatment. These advances together with the rapidly increasing knowledge of neural networks and their interconnectivity will lead to the formulation of new hypotheses on the cause and treatment of eating disorders.
While the evidence suggests that neuromodulation treatments have potential, as probes of illness mechanisms and as potential interventions in the treatment of eating disorders and obesity, much of this potential is still waiting to emerge. Much needs to be learnt about patient selection, intervention parameters, treatment targets, and how to optimize protocols. Neurocognitive, neural, and genetic predictors of outcome may help to individualize protocols and deliver personalized treatment.
At present, the rationale for use of one NIBS procedure over another is unclear. Ultimately, this may be mostly influenced by practical considerations, such as costs, availability, and commercial interests. In this respect, it is noted that portable tDCS devices are available, which can be used at home.
Neuromodulation technologies continue to evolve, and for example, in the case of NIBS, are increasingly allowing more precise targeting of treatment, use of increasingly briefer and more powerful treatment protocols, probing deeper brain areas, and stimulating multiple brain targets simultaneously [4 && ]. There is emerging evidence suggesting that these kinds of interventions may work synergistically when applied with different forms of cognitive training, as yet this combination The RCT is one of the first to test the effectiveness of EEG-neurofeedback for binge eating by comparing the outcomes with mental imagery or waitlist over a period of 3 months. 41.
